Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Basal Cell Cancer
New basal cell cancer study findings have been reported by D.F. Butler and co-researchers
February 17th, 2009
"Imiquimod 5% cream is currently approved for treatment of nonfacial, superficial basal cell carcinomas (BCCs). Topical imiquimod might be a reasonable candidate for adjunctive therapy of nodular, nasal BCCs before Mohs surgery," researchers in the United States report. "To observe the effectiveness of imiquimod 5% cream in reducing the number of Mohs stages, defect size, cost of Mohs surgery, and reconstruction. Patients applied the study medication nightly for 6 weeks with occlusion followed by a 4-week rest period before Mohs surgery was performed. No differences were demonstrated in the number of Mohs stages, defect sizes, or costs between the two groups, possibly...
Source: Cancer Weekly (2009-02-17)
|
